

CIS 2011 ANNUAL MEETING

May 19-22, 2011
Swissôtel ~ Chicago, IL



CIS Clinical
Immunology
Society

FINAL PROGRAM



Welcome to the 2011 CIS Annual Meeting!

Welcome to the 2011 CIS Annual Meeting in Chicago! The goal of the CIS leadership and Program Committee was to have a multi-disciplinary meeting with a broad focus where attendees can learn about research techniques used in other specialties of medicine and apply those techniques to their own research. We feel we have accomplished this with collaboration amongst our corporate supporters. This meeting is unique in that, our corporate supporters had the opportunity to sponsor educational sessions which allowed them to select the topic and speakers for their sessions.

The CIS leadership is excited about the 2011 Annual Meeting and we look forward to bringing accomplished clinical researchers together to present what is sure to be outstanding science.

Thank you for joining us!

Sincerely,

Steven M. Holland, MD
 CIS President
*Annual Meeting Program Committee
 Co-Chair*

Daniel Adelman, MD
 CIS Secretary – Treasurer
*Annual Meeting Program Committee
 Co-Chair*

TABLE OF CONTENTS

- About CIS & Council Pg 1
- Advanced PID School Faculty Pg 2
- Annual Meeting Program Committee..... Pg 3
- Annual Meeting Presenter Disclosures Pgs 4-6
- CME Information Pg 6
- General Meeting Information Pg 7
- Exhibit Hall Information Pgs 8-10
- Chicago Visitor Information Pg 11
- Program at-a-glance Pgs 15-16
- Advanced PID School Schedule..... Pgs 17-18
- Annual Meeting Schedule Pgs 19-22
- Poster Listing..... Pgs 23-26



CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



ABOUT CIS

The Clinical Immunology Society (CIS), established in 1986, is the key inter-disciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. CIS is an international professional organization which includes more than 600 clinicians, investigators, and trainees.

The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders.

The primary objectives and purposes of CIS are:

- to facilitate the interchange of ideas and information among physicians and other investigators who are concerned with immunological/inflammatory diseases;
- to promote research on the causes and mechanisms of diseases relating to the immune system and, as a result, to unify concepts of disease pathogenesis;
- to encourage investigators and clinicians to share in their knowledge of immunologically active drugs and other interventions;
- to promote application and dissemination of recent advances in biomedical science for the prevention, diagnosis and treatment of diseases related to immunity and inflammation; and
- to foster excellence in research and medical practice.

CIS has a new journal! *Journal of Clinical Immunology*, now the official journal of CIS.

The *Journal of Clinical Immunology* is an international journal that helps researchers and academic clinicians keep current on investigative basic immunology and diseases related to the immune system. This well-established journal publishes articles on basic, translational, and clinical studies in all aspects of immunology, including animal models of human diseases.



2010-2011 CIS COUNCIL

PRESIDENT

Steven M. Holland, MD
National Institute of Allergy and Infectious Diseases, NIH

PAST PRESIDENT

Carl H. June, MD
University of Pennsylvania

PRESIDENT-ELECT

Matthias G. von Herrath, MD
La Jolla Institute of Allergy and Immunology

SECRETARY-TREASURER

Daniel C. Adelman, MD
University of California, San Francisco

ELECTED COUNCILORS

Lawrence B. Schwartz, MD, PhD
Virginia Commonwealth University

John M. Routes, MD
Medical College of Wisconsin

Donald B. Kohn, MD
University of California, Los Angeles

EDITOR-IN-CHIEF, JOURNAL OF CLINICAL IMMUNOLOGY

Thomas A. Fleisher, MD
Bethesda, MD

WEBSITE MEDICAL EDITOR

Robert A. Eisenberg, MD
University of Pennsylvania

APPOINTED COUNCILORS

Antonio Condino-Neto, MD, PhD
University of Sao Paulo

Kim Isaacs, MD, PhD
University of North Carolina

Samia J. Khoury, MD
Brigham and Women's Hospital

Toshinori Nakayama, MD, PhD
Chiba University

Luigi D. Notarangelo, MD
Children's Hospital, Harvard Medical School

Hideho Okada, MD, PhD
University of Pittsburgh Cancer Institute



ADVANCED SCHOOL IN PRIMARY IMMUNODEFICIENCY DISEASES FACULTY

Charlotte Cunningham-Rundles, MD, PhD
Mt. Sinai Medical Center

Alexandra H. Filipovich, MD
Cincinnati Children's Hospital

Thomas A. Fleisher, MD
National Institutes of Health

Steven M. Holland, MD
National Institute of Allergy and Infectious Diseases, NIH

Kari C. Nadeau, MD, PhD
Stanford University

Joao Bosco Oliveira, MD, PhD
NIH Clinical Center

Jordan S. Orange, MD, PhD
Children's Hospital of Philadelphia

Kathleen E. Sullivan, MD, PhD
Children's Hospital of Philadelphia

Troy R. Torgerson, MD, PhD
University of Washington

THANK YOU TO OUR ADVANCED PID SCHOOL SUPPORTERS!

Baxter

CSL Behring

Biotherapies for Life™

GRIFOLS

octapharma

For the safe and optimal use of plasma

Stanford University

Talecris
BIOTHERAPEUTICS

CENTER FOR SCIENCE & EDUCATION



CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



ANNUAL MEETING PROGRAM COMMITTEE

CO-CHAIRS:

Daniel C. Adelman, MD
University of California, San Francisco

Steven M. Holland, MD
National Institute of Allergy and Infectious Diseases, NIH

COMMITTEE MEMBERS:

Antonio Condino-Neto, MD, PhD
University of Sao Paulo

Charlotte Cunningham-Rundles, MD, PhD
Mt. Sinai Medical Center

Dewton De Moraes Vasconcelos, MD, PhD
University of Sao Paulo Medical School

Robert A. Eisenberg, MD
University of Pennsylvania

Thomas A. Fleisher, MD
National Institutes of Health

Alexandra F. Freeman, MD
National Institute of Allergy and Infectious Diseases, NIH

Raphaela Goldbach-Mansky, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH

Hal M. Hoffman, MD
University of California, San Diego

Carl H. June, MD
University of Pennsylvania

Donald B. Kohn, MD
University of California, Los Angeles

Toshinori Nakayama, MD, PhD
Chiba University

Luigi D. Notarangelo, MD
Harvard Medical School

Jordan S. Orange, MD, PhD
Children's Hospital of Philadelphia

John M. Routes, MD
Medical College of Wisconsin

John L. Schmitz, PhD
University of North Carolina

Lawrence B. Schwartz, MD, PhD
Virginia Commonwealth University

Padmanee Sharma, MD, PhD
MD Anderson Cancer Center

Ricardo U. Sorensen, MD
LSU Health Sciences Center

Kathleen E. Sullivan, MD, PhD
Children's Hospital of Philadelphia

George C. Tsokos, MD
Beth Israel Deaconess Medical Center

James Verbsky, MD, PhD
Medical College of Wisconsin

Matthias G. von Herrath, MD
La Jolla Institute Allergy and Immunology





PROGRAM COMMITTEE & ANNUAL MEETING SPEAKER DISCLOSURES

Daniel C. Adelman, MD
Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals, Inc. – Employment receiving salary.

James Allison, PhD
Memorial Sloan-Kettering Cancer Center
Bristol Myers Squibb - Inventor of intellectual property receiving royalty.

Sarah K. Browne, MD
NIAID, NIH
There are no relationships to disclose.

Fredrick Bushman, PhD
University of Pennsylvania
There are no relationships to disclose.

Jean-Laurent Casanova, MD, PhD
The Rockefeller University
Pfizer – Research funding for invasive pneumococcal disease study receiving research grant through the university.

Marco Colonna, MD
Washington University School of Medicine
There are no relationships to disclose.

Antonio Condino-Neto, MD, PhD
University of Sao Paulo
There are no relationships to disclose.

Max D. Cooper, MD
Emory University
There are no relationships to disclose.

Carlo Croce, MD
Ohio State University
There are no relationships to disclose.

Charlotte Cunningham-Rundles, MD, PhD
Mount Sinai Medical Center
*Baxter – Research study on PID in NYC receiving research study.
Octapharma – On ICD code discrimination receiving research study.
Immune Deficiency Foundation – PI receiving participation in a cooperative grant.*

Syamal K. Datta, MD
Northwestern University
*Northwestern University – U.S. Patent No. 6,468,537 B1 (IP rights).
Northwestern University – U.S. Patent 11373894 (Filed)—(IP rights).*

Dewton De Moraes Vasconcelos, MD, PhD
University of Sao Paulo Medical School
There are no relationships to disclose.

Robert A. Eisenberg, MD
University of Pennsylvania
Genentech/Roche – Advisory Committee member receiving consulting fee.

Thomas A. Fleisher, MD
National Institutes of Health
There are no relationships to disclose.

Alexandra F. Freeman, MD
NIAID, NIH
There are no relationships to disclose.

Mitchell Garber
Alvine Pharmaceuticals, Inc.
Alvine Pharmaceuticals, Inc. – Employment receiving salary.

Raphaella Goldbach-Mansky, MD
NIAMS, NIH
There are no relationships to disclose.

Douglas Golenbock, MD
University of Massachusetts
IDERA – Consultant and member of scientific advisory board receiving consultant fee.

Hal M. Hoffman, MD
University of California, San Diego
*Regeneron - Consulting receiving consulting fee.
Novartis - Consulting receiving consulting fee.
SOBI - Consulting receiving consulting fee.
Glaxo Smith Kline - Research receiving research funds.
Idera - Research receiving research funds.
Ardea - Research receiving research funds.*

Steven M. Holland, MD
NIAID, NIH
There are no relationships to disclose.

Bana Jabri, MD, PhD
University of Chicago
There are no relationships to disclose.

Carl H. June, MD
University of Pennsylvania
*Celldex Therapeutics - Scientific advisory board receiving consulting fee.
Globeimmune - Scientific advisory board receiving consulting fee.*

Sun Jung Kim, MD
Feinstein Institute for Medical Research
There are no relationships to disclose.

Donald B. Kohn, MD
University of California, Los Angeles
There are no relationships to disclose.

Klaus Ley, MD
La Jolla Institute for Allergy & Immunology
*Targeson – Founder receiving ownership interest.
MicroPractice Proteomics – Founder receiving ownership interest.
Centocor – Consultant receiving consultant fee.*

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



PROGRAM COMMITTEE & ANNUAL MEETING SPEAKER DISCLOSURES

Ian Lipkin, MD

Columbia University

Pathogenica – Scientific advisory board receiving stock options.

Akonn – Scientific advisory board receiving stock options.

Prosetta – Scientific advisory board receiving stock options.

Diane Longo, PhD

Nodality

Nodality – Employment receiving salary, shareholder.

Otávio C. Marques, MSc

University of Washington

There are no relationships to disclose.

Claudia Mauri, PhD

University College London

There are no relationships to disclose.

Ahmed Metwali, PhD

University of Iowa Hospitals & Clinics

There are no relationships to disclose.

Enrique Montero, MD, PhD

Center Molecular Immunology

There are no relationships to disclose.

Toshinori Nakayama, MD, PhD

Chiba University

There are no relationships to disclose.

Luigi D. Notarangelo, MD

Harvard Medical School

Immune Disease Institute - chairmanship of scientific advisory board receiving honoraria.

Michel Nussenzweig, MD, PhD

The Rockefeller University

There are no relationships to disclose.

Jordan S. Orange, MD, PhD

Baxter Healthcare – Consultant and speaker receiving consulting fee and speaker honoraria.

Talecris Biotherapeutics – Consultant receiving consulting fee.

CSL Behring – Consultant receiving consulting fee.

IBT Reference Laboratories – Scientific advisory board member receiving consulting fee.

John J. O'Shea, MD

National Institutes of Health

There are no relationships to disclose.

Harlan Robins, PhD

Fred Hutchinson Cancer Research Center

Adaptive TCR Corp – Founder and consultant receiving stock and consulting fee.

John M. Routes, MD

Medical College of Wisconsin

There are no relationships to disclose.

John L. Schmitz, PhD

University of North Carolina

There are no relationships to disclose.

L. S. Schulz

Wilhelmina Children's Hospital Utiect

There are no relationships to disclose.

Sabrina Scroggins, BS

University of Iowa

There are no relationships to disclose.

Lawrence B. Schwartz, MD, PhD

Virginia Commonwealth University

Hycult, Millipore, BioLegend, Santa Cruz: mAbs - Inventor receiving royalties.

Genentech, Novartis, GSK, Pharming, Ception, Cephalon - Site PI receiving research support, clinical trials.

Genentec, Mast Cell Pharm - Scientific advisory board receiving honoraria.

Cecil's Textbook of Medicine, Up-to-Date - Chapter author receiving royalties.

J Clinical Immunology - Springer - Associate editor receiving honorarium.

Sanofi-Avenis, Exoxemis - Consultant receiving consulting fee.

NIH Study Section - Grant review receiving honorarium.

ACAAI, AAAAI, ATS, Stanford, Univ Virginia - Lectures receiving honorarium.

Padmanee Sharma, MD, PhD

MD Anderson Cancer Center

Bristol-Myers Squibb – Advisory committee receiving honoraria.

Dendreon – Advisory committee receiving honoraria.

Erin F. Simonds, BS

Stanford University School of Medicine

There are no relationships to disclose.

Ricardo U. Sorensen, MD

LSU Health Sciences Center

Baxter – LATAM advisory committee receiving honoraria.

Talecris – Speaking and teaching receiving honoraria.

Netsle – Speaking and teaching receiving honoraria.

Kathleen E. Sullivan, MD, PhD

Children's Hospital of Philadelphia

Immune Deficiency Foundation – Consulting immunologist receiving consulting fee.

Suzanne Topalian, MD

John's Hopkins University

Bristol-Myers Squibb – Consultant, uncompensated.

Bristol-Myers Squibb – Principal investigator receiving sponsored laboratory research.

Amplimmune, Inc. – Consultant receiving consulting fee (spouse)



PROGRAM COMMITTEE & ANNUAL MEETING SPEAKER DISCLOSURES — continued

Simone Treiger Sredni, MD, PhD

Children's Memorial Hospital

There are no relationships to disclose.

George C. Tsokos, MD

Beth Israel Deaconess Medical Center

Lilly – Data monitoring committee receiving consulting fee.

HGS - Data monitoring committee receiving consulting fee.

Genentech - Data monitoring committee receiving consulting fee.

Merck – Lecture receiving honoraria.

Millenium - Lecture receiving honoraria.

Elsevier – Editorial work receiving stipend.

Dale T. Umetsu, MD, PhD

Harvard Medical School

Genentech – Complete study receiving study drug for clinical trial.

NIH – Complete studies receiving grant support.

James Verbsky, MD, PhD

Medical College of Wisconsin

llumina - Gave a talk on the use of sequencing in disease diagnosis receiving honorarium.

Matthias G. von Herrath, MD

La Jolla Institute Allergy & Immunology

NovoNordisk – Consultation on type 2 diabetes receiving consultation fee.

BayHill Therapeutics Genentech – DNA vaccines for T1D receiving consultation fee.

Novartis – For presentation in Basel receiving honorarium.

Kazuki Yamasaki, MD

Chiba University

There are no relationships to disclose.

CONTINUING MEDICAL EDUCATION INFORMATION

PURPOSE

We seek to introduce the most current concepts in etiology, pathogenesis, and treatment of immune mediated disease to an audience of clinicians, investigators, and trainees in the areas of immunology, immunodeficiency, cancer, allergy, and infectious diseases. We anticipate that delegates will gain a deeper understanding of disease mechanisms and manifestations and will appreciate broader aspects of immune regulation of disease.

CONTENT AREA

This meeting will cover the pathogenesis of a diverse group of immunodeficiencies, autoimmunity, and cancer therapy and the appropriate therapeutics to treat these diseases.

TARGET AUDIENCE

Clinicians, investigators, and trainees in the areas of immunology, immunodeficiency, cancer, allergy, and infectious diseases.

EXPECTED RESULTS

- Appreciate the expanding roles of the immune system in disease manifestation;
- Recognize opportunities for immune intervention in disease pathogenesis;
- Understand mechanisms of immune activation and immunodeficiency;
- Become acquainted with immune manipulation in cancer therapy.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Clinical Immunology Society (CIS). The CIS is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Clinical Immunology Society designates this live activity for a maximum of 15.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CLAIMING CME

All registered delegates will receive an email at the conclusion of the conference with a link and instructions for claiming CME.

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



MEETING INFORMATION

EXHIBIT HALL HOURS

Exhibitors provide the latest information on products and services available to physicians, researchers and Allied Health professionals in the field of immunology. Take this valuable opportunity to meet with companies and organizations, specializing in all areas of the field.

Exhibitor Move-in Hours

Thursday, May 19 8:00am – 5:00pm

Exhibit Hours

Thursday, May 19 7:00pm – 9:00pm

Friday, May 20 10:30am – 1:30pm

5:30pm – 7:30pm

Saturday, May 21 10:30am – 1:30pm

5:30pm – 7:30pm

Exhibitor Dismantle Hours

Sunday, May 22 7:00am – 1:00pm

POSTER RECEPTIONS

Poster receptions are held in the exhibit hall and authors will be present with their posters during receptions.

Poster Reception Hours

Thursday, May 19 7:00pm – 9:00pm

Friday, May 20 5:30pm – 7:30pm

Saturday, May 21 5:30pm – 7:30pm

MEETING LOCATION

All educational sessions, posters, exhibits, and registration held as part of the CIS Annual Meeting will take place at the Swissôtel Chicago.

Swissôtel Chicago
323 E. Wacker Drive
Chicago, IL 60601
Phone: (312) 565-0565

REGISTRATION DESK

Swissôtel Chicago ~ Zurich Ballroom Foyer

Registration Desk Hours

Wednesday, May 18 5:00pm – 8:00pm

Thursday, May 19 7:00am – 7:00pm

Friday, May 20 7:00am – 7:00pm

Saturday, May 21 7:00am – 7:00pm

Sunday, May 22 7:00am – 11:00am

PUBLISHING OF ABSTRACTS

The abstracts submitted to the Annual Meeting will be published in a special issue of *Journal of Clinical Immunology*, the official journal of the Clinical Immunology Society.

ACCESSIBILITY

If you require special arrangements in order to fully participate in the CIS Annual Meeting, please speak with a CIS staff member at the registration desk.

NAME BADGES

All registered attendees at the CIS Annual Meeting will receive a name badge as part of their registration packet. These badges should be worn at all times as they will be used to control access to sessions and activities.

SMOKING

Smoking is prohibited at all Annual Meeting sessions and events.

EVALUATIONS

Delegates will have the opportunity to provide feedback on their experience at the CIS Annual Meeting. After the meeting all registered delegates will receive an online evaluation to complete. Evaluations are an important part in helping us to improve our educational sessions so please be sure to complete it!

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



EXHIBITORS

Booth: 103

Company: Kronus

KRONUS® will be presenting information on its complete line of immunoassay test kits useful in the diagnosis and management of various organ-specific autoimmune diseases. The Products -- which encompass both routine and esoteric testing applications -- offer the exceptional performance, robustness and convenience for which KRONUS continues to be recognized.

Please take a few moments to visit our exhibit and learn more about the complete KRONUS product line.

Booth: 104 – 105

Company: Baxter

Providing a comprehensive range of therapeutic proteins derived from plasma and through innovative recombinant technology. These high-quality, leading therapies are used to enhance the lives of patients requiring support for hemostasis, immune deficiencies, Alpha-PI deficiency, and hemophilia and other blood-related disorders.

Booth: 106 – 107

Company: BioTherapeutics

BioTherapeutics, a unit of Baxter's BioScience business, focuses on three key therapeutic areas: immunology, pulmonology and critical care. The BioTherapeutics R&D booth will be staffed by Baxter Clinical and Medical Affairs representatives and offers an interactive pipeline overview, including investigational trials in immunology. For more information on BioTherapeutics, please visit www.baxter.com.

Booth: 108

Company: Crescent Healthcare

Crescent Healthcare is a home infusion therapy company focused on providing comprehensive home IVIG and SCIG services. Crescent Healthcare's specialized IVIG clinical intake centers consist of clinical pharmacists, registered nurses, and intake specialists. Our services include authorization procurement, clinical support, infusion nurse scheduling, management and education, and clinical follow-up to assess and manage side effects and to monitor response to therapy. Crescent Healthcare is contracted with most state, federal, military and private insurances and we provide our comprehensive IVIG and SCIG services to patients across the USA.

Booth: 109 – 110

Company: CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services.

The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns and shock.

CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslobehring-us.com.

Booth: 111

Company: USIDNET

The United States Immunodeficiency Network (USIDNET) was created to address issues in research for the more than 150 genetically determined primary immune deficiency diseases (PIDD).

USIDNET is funded to develop and maintain a Web access Registry to obtain longitudinal data on PIDD patients nationwide, and form a cooperative network of PIDD investigators. USIDNET also provides leadership and mentoring opportunities for clinical and basic investigators new to the field, offers educational opportunities to young investigators and travel scholarships to domestic and international scientific meetings, and maintains a Repository for cells and DNA from individuals affected by PIDD. For more information, visit www.usidnet.org.

Booth: 112

Company: Adaptive TCR Technologies

Adaptive's Immune System Profiling service provides a biochemical method for parallel sequencing of millions of TCRs with the data analysis capability of a secure proprietary relational database management system. Adaptive's immunoSEQ system combines the capabilities of ultrahigh-throughput DNA sequencing with a proprietary sequencing methodology and a powerful bioinformatics software suite to provide exceptionally deep access to T cell repertoires.



Booth: 113

Company: Medical College of Wisconsin

The Clinical Immunodiagnostic & Research Laboratory (CIRL) at the Medical College of Wisconsin (MCW) provides a comprehensive panel of diagnostic services using state-of-art multicolor flow cytometric instrumentation for detection, diagnosis and monitoring of immunologic diseases. The CIRL plays an integral role in collaborative efforts with the multi-disciplinary Primary Immunodeficiency (IDC), Blood & Marrow Transplant and Infectious Diseases Clinics at the Children's Hospital of Wisconsin (CHW). IDC has been recognized as the only Jeffrey Modell Diagnostic & Patient Referral Center in the Wisconsin since 2007 and first center in the USA to initiate statewide newborn screening for Severe Combined Immunodeficiency (SCID).

Booth: 114

Company: US Bioservices

For more than 16 years, US Bioservices has delivered nationwide specialty pharmacy and nursing services that meet the unique needs of patients needing infusions. Through our Pathpoint Ig program, we provide access to all available brands of immune globulin, coordinate comprehensive nursing services for every infusion and deliver scheduled status reports to the physician. In addition, we invest additional time in verifying each patient's insurance benefits, attempting to minimize out of pocket expenses whenever possible. Our dedicated clinical staff of nurses and pharmacists assures that all patients receive the quality, high touch services that lead to maximized therapeutic success.

Booth: 115

Company: Accredo

Accredo Health Group, Inc., is a recognized leader in the specialty pharmacy industry, providing targeted therapy support to patients with rare and complex conditions for over 25 years. As a wholly owned subsidiary of Medco, Accredo is one of the largest specialty pharmacy providers in the United States.

Booth: 116

Company: Talecris Biotherapeutics

Talecris Biotherapeutics invites you to visit booth #116 to learn more about our full range of plasma products including Gamunex®-C, Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified. We are pleased to have this opportunity to contribute to the success of this meeting.

Booth: 117

Company: ViraCor IBT Laboratories

Viracor-IBT Laboratories is redefining patient care through innovative molecular and immune-diagnostics. With a menu of more than 2,000 tests and dedication to excellence in science and client service, the company offers an unparalleled array of immunology, infectious disease and allergy testing with the fastest turnaround in the industry. Viracor-IBT serves physicians, hospitals, commercial laboratories, and biopharmaceutical companies throughout the United States. To learn more about our menu and testing services, visit us at www.ViraCorIBT.com

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



CIS / BAXTER SCHOLARSHIP PROGRAM AWARD WINNERS

Thanks to a generous grant from Baxter BioScience, we were able to offer one (1) \$60,000 Fellowship Award and one (1) \$85,000 Junior Faculty Award to these two promising immunologists who have demonstrated a commitment to the study of primary immunodeficiency as a career path. Funding is to support the education and research endeavors of these individuals.

Congratulations to the Senior Fellowship Award Winner: Lisa Forbes, MD, *Children's Hospital of Pennsylvania*

Congratulations to the Junior Faculty Award Winner: Jolan Walter, MD, PhD, *Children's Hospital Boston*

CHICAGO VISITOR INFORMATION

One of the world's most magnificent skylines provides the backdrop for a splendid stretch of coastline along Lake Michigan. This is Chicago. Check out some of the city's exciting neighborhoods:

THE LOOP

Extraordinary shopping, exceptional dining, and theatrical productions on landmark stages are hallmarks of this famed district in the heart of the city. The Loop's cultural edge is honed by the glorious Art Institute of Chicago, Chicago Symphony Orchestra, Lyric Opera of Chicago, and Chicago Cultural Center, and others.

MAGNIFICENT MILE

Just stroll Michigan Avenue north from the Chicago River to discover why it's called the Magnificent Mile. At the avenue's north end are Oak Street's upscale boutiques. Attractions include historic Water Tower, Museum of Contemporary Art, John Hancock Observatory, and exciting Navy Pier.

RIVER NORTH

Art, antiques, and restaurants abound in this chic neighborhood just west of North Michigan Avenue. Walk north from the massive Merchandise Mart to see galleries that rival those of Manhattan's Soho. And many of the celebrated chefs/restaurateurs who have placed Chicago on the world's culinary map are at home in River North eateries.

OLD TOWN

A 15-minute cab ride north of downtown, Old Town is home to The Second City's celebrated improvisational comedy, Tony Award-winning Steppenwolf Theatre Company, and the Chicago History Museum, plus a delightful array of restaurants and shops.

LINCOLN PARK/WRIGLEYVILLE

Blues and dance clubs, restaurants for every taste, and shops mix with residences in these neighborhoods. A 10-minute cab ride north of downtown are amazing Lincoln Park Zoo, Lincoln Park Conservatory, and The Peggy Notebaert Nature Museum. Chants of "Go Cubs Go" fill the air when the Chicago Cubs are at home at Wrigley Field, about eight blocks further north.

NEAR SOUTH SIDE

Along the lakefront north from Chicago White Sox ballpark U.S. Cellular Field are McCormick Place and Soldier Field, home arena of the NFL Chicago Bears. World-class cultural institutions Shedd Aquarium, Field Museum, and Adler Planetarium share beautiful lakefront grounds.

Proud sponsor of the CIS Annual Meeting



Therapy and Beyond Baxter's ongoing commitment

For nearly 25 years, Baxter has provided the primary immunodeficiency community with trusted IgG products that help patients reduce the risk of infection.

Today, we continue our commitment to improving patient outcomes through partnerships with clinical experts and sponsorships of patient advocacy groups like the **Immune Deficiency Foundation** and the **Jeffrey Modell Foundation**.

We remain dedicated to answering unmet needs through clinical initiatives and programs that offer an essential layer of support for patients and healthcare providers.

Visit the Baxter Booth, #104-#105, to learn more.

Committed to advancing therapies and services
in the field of primary immunodeficiency



CSL Behring

A leader in rare-disease therapies

At CSL Behring, we are committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. We have a 100-year heritage of quality and safety, and offer an extensive range of plasma-derived and recombinant therapies that are used in:

Immunology • Pulmonology • Coagulation • Critical care

With our continued focus on innovation, we are leaders in developing new and enhanced "Biotherapies for Life."

Biotherapies for Life™ **CSL Behring**

Stop by booths 109 and 110.

©2010 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA
www.CSLBehring-us.com 11-MGD-011 9/2010

Visit www.CSLBehring-us.com

What matters most...People



For over 70 years, Grifols has been dedicated to quality, safety and efficacy in the products we manufacture

Visit our website at www.grifolsusa.com to learn about Grifols' newest product

CTP03-1-05-0

GRIFOLS

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



2011 CIS ANNUAL MEETING PROGRAM AT-A-GLANCE

	ZURICH FOYER	ZURICH ABCD	ZURICH EFG	ST. GALLEN I
WEDNESDAY, MAY 18				
3:30pm - 5:00pm				JoCI Ops Meeting
5:00pm - 8:00pm	Registration Open			
5:00pm - 7:00pm				CIS Council Meeting
7:00pm - 8:00pm			Advanced PID School Opening Lecture	
8:00pm - 9:30pm	PID Poster Reception			
THURSDAY, MAY 19				
7:00am - 7:00pm	Registration Open			
7:30am - 8:30am	Breakfast			
8:30am - 5:30pm			Advanced PID School	
12:00pm - 1:00pm	Lunch			
6:00pm - 7:00pm			Annual Meeting Opening Keynote	
7:00pm - 9:00pm		Exhibit & Poster Hall Open / Annual Meeting Opening Reception		
FRIDAY, MAY 20				
7:00am - 7:00pm	Registration Open			
7:30am - 8:30am		Breakfast		
8:30am - 10:45am			The Micro Session: How Small Can You Go?	
10:30am - 1:30pm		Exhibit & Poster Hall Open		
11:00am - 12:30pm			Baxter Symposium	
12:30pm - 1:30pm		Lunch		NIT/FIT Meet-and-Greet
1:30pm - 3:00pm			CSL Symposium	
3:30pm - 5:30pm			T Cells: How Do They Handle Commitment?	
5:30pm - 7:30pm		Exhibit & Poster Hall Open		
5:30pm - 6:00pm			CIS Business Meeting	
5:30pm - 7:30pm		Poster Reception		
6:00pm - 6:30pm				CIS Publications Committee Meeting
6:30pm - 8:00pm				JoCI Editorial Board Meeting



2011 CIS ANNUAL MEETING PROGRAM AT-A-GLANCE

	ZURICH FOYER	ZURICH ABCD	ZURICH EFG	ST. GALLEN I
SATURDAY, MAY 21				
7:00am - 7:00pm	Registration Open			
7:00am - 8:30am		Breakfast	Baxter Symposium	
8:30am - 10:45am			Immune Checkpoint Blockade as Cancer Therapy	
10:30am - 1:30pm		Exhibit & Poster Hall Open		
11:00am - 12:30pm			Future Technologies / Sequencing	
12:30pm - 1:30pm		Lunch		
1:30pm - 3:00pm			New Novel Diagnostics	
3:30pm - 5:30pm			B Cells: They Regulate Too You Know	
5:30pm - 7:30pm		Exhibit & Poster Hall Open/Poster Reception		
SUNDAY, MAY 22				
7:00am - 11:00am	Registration Open			
7:30am - 8:30am	Breakfast			
8:30am - 10:45am			Innate Immunity, Finally Getting Some Respect	
11:00am - 12:00pm			Closing Session: The Ways Forward	

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



2011 ADVANCED SCHOOL IN PRIMARY IMMUNODEFICIENCY DISEASES SCHEDULE OF EVENTS

MAY 18 — 19, 2011

WEDNESDAY, MAY 18, 2011

7:00 pm Opening Keynote Lecture
Moderator: Charlotte Cunningham-Rundles, MD, PhD
IL-2 and IL-15 in the Life and Death of Lymphocytes: Implications for the Pathogenesis and Treatment of PID, Autoimmune Disorders and Leukemia
Thomas A. Waldmann, MD
National Cancer Institute, NIH

8:00 pm Opening Welcome Reception & Poster Session

10:40am – 11:30am **Antibody Defects**
Moderator: Charlotte Cunningham-Rundles, MD, PhD

10:40am Loss of B Cell Function: Causes, Complications and Outcomes
Charlotte Cunningham-Rundles, MD, PhD
Mount Sinai Medical Center

11:00am Characterization of CVID Clinical Phenotypes Using Whole Blood Transcriptional Signatures
Joon H. Park, MD
Mount Sinai Medical Center

THURSDAY, MAY 19, 2011

8:00am Breakfast

8:30am – 10:10am **Innate Immunity**
Moderator: Steven M. Holland, MD

8:30am Innate Immunity: What's New in Something So Old?
Steven M. Holland, MD
NIAID, NIH

8:50am NEMO-syndrome Mutations and Ubiquitin-binding
Eric Hanson, MD
NIAMS, NIH

9:05am A Role for STAT3 Signaling in the Development and Maintenance of Human T cell Memory
Joshua D. Milner, MD
NIAID, NIH

9:20am The New Face of Leukocyte Adhesion Deficiency Type
Gulbu Uzel, MD
NIAID, NIH

9:25am Mycobacterial Infections in 59 Patients with Chronic Granulomatous Disease
Saul O. Lugo Reyes, MD
National Institute of Pediatrics

9:30am Skewed Effector T Lymphocytes and Cytokine Profile from Gut Lamina Propria Mononuclear Cells in Chronic Granulomatous Disease
Britanny Winckler, BS
NIAID, NIH

9:35am IL-12/23-IFN-gamma Axis Defects Impair Human NADPH Oxidase System Activation
Walmir C. Aragão-Filho, MSc
University of São Paulo

9:40am Interactive Discussion

10:10am Morning Break

11:15am Gastrointestinal Symptoms in Pediatric Common Variable Immunodeficiency: Results from Questionnaires and Fecal Sampling
Annick A. van de Ven, MD
University Medical Center Utrecht

11:20am Evolution of IgA Deficient Patients with more than 10 Years of Diagnosis
Cristina Kokron, MD, PhD
University of São Paulo

11:25am Interactive Discussion

12:00pm Lunch

1:00pm – 2:00pm **Registries**
Moderator: Kathleen E. Sullivan, MD, PhD

1:00pm Hypogammaglobulinemia in DiGeorge Syndrome: A Registry Approach
Kathleen E. Sullivan, MD, PhD
Children's Hospital of Philadelphia

1:15pm Primary Immunodeficiency Diseases in 910 Brazilian Patients of Different Age Groups
Magda M. Carneiro-Sampaio, MD, PhD
University of São Paulo

1:20pm Primary Immunodeficiency Diseases in Iran: A Decade of Progress in Molecular Diagnosis of Immunodeficient Patients
Nima Rezaei, MD, PhD
Tehran University of Medical Sciences

1:25pm SCID and Wiskott-Aldrich Syndrome in New York State: Diagnosis, Complications, and Costs
Elena Resnick, MD
Mt. Sinai Medical Center

1:30pm Interactive Discussion



2011 ADVANCED SCHOOL IN PRIMARY IMMUNODEFICIENCY DISEASES MAY 18 — 19, 2011

SCHEDULE OF EVENTS

2:00pm – 3:30pm	Immune Dysregulation	4:00pm –5:45pm	Cellular Defects
	<i>Moderators: Troy Torgerson, MD, PhD & Joao Bosco Oliveira, MD, PhD</i>		<i>Moderator: Donald B. Kohn, MD</i>
2:00pm	Immune Dysregulation Syndromes: From ALPS to IPEX Troy Torgerson, MD, PhD <i>University of Washington</i> Joao Bosco Oliveira, MD, PhD <i>NIH Clinical Center</i>	4:00pm	Clinical Gene Therapy for ADA-SCID Donald B. Kohn, MD <i>UCLA</i>
2:20pm	Alemtuzumab: An Important Agent for the Treatment of HLH and for HCT Rebecca A. Marsh, MD <i>Cincinnati Children's Hospital</i>	4:20pm	Epigenetic Regulation in X-linked Thrombocytopenia vs. Wiskott-Aldrich Syndrome Kari Nadeau, MD, PhD <i>Stanford University</i>
2:35pm	Identification of Treg Developmental and Functional Defects in Subjects with STAT5b Deficiency Kari Nadeau, MD, PhD <i>Stanford University</i>	4:35pm	3-dimensional poly (3-caprolactone) Scaffold Containing Skin-derived Fibroblasts and Keratinocytes Supports in Vitro HSCs Differentiation in T Lineage-committed Cells Ilaria Vigliano <i>Federico II University, Naples, Italy</i>
2:50pm	Novel Insights into the Pathogenesis of Human IL-2R alpha Deficiency Leading to Chronic Infections and Autoimmune Tissue Damage Rosa Bacchetta, MD <i>HSR-TIGET</i>	4:40pm	Characterization of Autoantibody Profile Among Patients with Primary Immunodeficiency Secondary to RAG Mutations Jolan E. Walter, MD, PhD <i>Children's Hospital Boston</i>
2:55pm	Unusual Presentation of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) Katherine A. Gonzaga, MD <i>Medical College of Wisconsin</i>	4:45pm	Autoimmunity and Persistent Viral Infection: Case Report of Two Mexican Siblings with DOCK-8 Mutation Leticia Hernandez-Nieto <i>National Institute of Pediatrics</i>
3:00pm	FAS Haploinsufficiency is a Common Disease Mechanism in the Human Autoimmune Lymphoproliferative Syndrome Joao Bosco Oliveira, MD, PhD <i>NIH Clinical Center</i>	4:50pm	Potential Extrathymic Lymphopoiesis in a Athymic Human Fetus Carrying Homozygous FOXP1 Mutation Ilaria Vigliano <i>Federico II University</i>
3:05pm	Interactive Discussion	4:55pm	Challenges in Newborn Screening for SCID Kirsten Kloepper, MD <i>University of Wisconsin</i>
3:30pm	Afternoon Break	5:00pm	Interactive Discussion
		5:30pm	Closing Remarks

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



2011 ANNUAL MEETING MAY 19 – 22, 2011 SWISSÔTEL ~ CHICAGO, IL SCHEDULE OF EVENTS

THURSDAY, MAY 19

6:00pm – 7:00pm **The All Children's, St. Petersburg Robert A. Good Memorial Lecture**

Evolution of the Adaptive Immune Response

Max Cooper, MD

Emory University

Credit: 1 CME

Upon completion of this session, participants should be able to: understand key similarities and strikingly parallels between the adaptive immune system in primitive jawless vertebrates (lampreys) and higher vertebrates; become familiar with a new type of monoclonal antibodies and their potential use in immunodiagnostic tests; and review flow cytometry as a diagnostic tool in characterization of normal and malignant cells.

7:00pm – 9:00pm **Poster Reception & Annual Meeting Opening Reception**

Supported in part by  **KRONUS**
Your Source for Disease Autoantibody Test Kits
www.kronus.com

FRIDAY, MAY 20

7:30am – 8:30am Breakfast

8:30am – 10:45am **The Micro Session: How Small Can You Go?**

Credit: 2.25 CME

Upon completion of this session, participants should be able to: provide an understanding of the role of microRNA in control of gene expression; and provide evidence of the function of microRNAs in the pathophysiology of Juvenile dermatomyositis.

8:30am – 9:00am MicroRNAs and Immune Control

Carlo Croce, MD

Ohio State University

9:00am – 9:30am Microbiome

Fredrick Bushman, PhD

University of Pennsylvania

9:30am – 10:00am Microbe Hunting

W. Ian Lipkin, MD

Columbia University

10:00am – 10:15am Pathophysiology of Untreated Juvenile Dermatomyositis Muscle: Hypoxia and Apoptosis are Regulated by MicroRNA's

Simone Treiger Sredni, MD, PhD

Children's Memorial Hospital

10:15am – 10:30am Advantages of Helminth Conditioning over Therapeutic Antibody in Treatment of IBD

Ahmed Metwali, PhD

University of Iowa College of Medicine

10:30am – 10:45am Adenovirus PCR-positivity in Stool Precedes Intestinal Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

L. Schulz, BSc

University Medical Center / Wilhelmina Children's Hospital

10:45am – 11:00am Break

11:00am – 12:30pm **Medical Crossfire: Comparing Routes of IgG Administration for Primary Immunodeficiency Disorders**

11:00am – 11:15am Overview of Current Routes of IgG Administration

Troy Torgerson, MD, PhD (Chair)

Assistant Professor, Pediatric Immunology/ Rheumatology

University of Washington, Department of Pediatrics

Co-Director, Immunology Diagnostic Laboratory Center for Immunity and Immunotherapies Seattle Children's Research Institute

11:15am – 11:35am Why I Use IVIG

Vincent R. Bonagura, MD

Chief, Allergy/Immunology

Cohen Children's Medical Center of New York North Shore-Long Island Jewish Health System

Associate Chair, Pediatrics

Professor of Pediatrics, Microbiology, and Immunology

Albert Einstein College of Medicine

11:35am – 11:55am Why I Use SCIG

Ralph S. Shapiro, MD

Director

Midwest Immunology Clinic

Plymouth, Minnesota

11:55am – 12:30pm Expert Debate and Q&A

Moderator: Troy Torgerson, MD, PhD

Learning Objectives

Following participation you should be able to:

- Discuss clinical guidance for the use of IVIG and SCIG
- Discuss tolerability and adverse event management for IVIG and SCIG in naïve vs. experienced patients, and issues affecting tolerability
- Assess pharmacokinetic benefits of IVIG and SCIG

Sponsored by InforMEDical Communications, Inc.

Supported by an educational grant from **Baxter**

12:30pm – 1:30pm Lunch Break



FRIDAY, MAY 20 — CONTINUED

1:30pm – 3:00pm Primary Immunodeficiency - Evolving Concepts in the Diagnosis and Treatment

Speaker

Jordan Orange MD, PhD

Associate Professor of Pediatrics

University of Pennsylvania School of Medicine

Children's Hospital of Philadelphia, Division of Immunology

Topics of Discussion:

1. Recent genomic advances in antibody deficiencies
2. Widescale use of genetically oriented screening approaches for combined immune deficiency
3. Optimizing therapy for antibody-deficient patients and considerations specific to intravenous and subcutaneous immune globulin administration

Additional speakers presenting their research on Newborn Screening for Combined Immune Deficiency:

Newborn Screening for SCID in New York State

Artemio M. Jongco III, MD, PhD, MPH

Fellow in Allergy and Immunology

North Shore-Long Island Jewish Health System

Newborn Screening for SCID: the Wisconsin Experience (2008 - 2011)

James Verbsky, MD, PhD

Assistant Professor of Pediatrics

Medical College of Wisconsin

Division of Asthma, Allergy and Immunology, and Rheumatology

*This session is supported by **CSL Behring**
Biotherapies for Life™*

3:00pm – 3:30pm Break

3:30pm – 5:30pm

T Cells: How Do They Handle Commitment?

Credit: 2 CME

Upon completion of this session, participants should be able to: apply translational medicine to autoimmune diseases based on CD6 targeted approaches; and have an understanding that a prolonged lymphocyte depletion may not be required to induce a therapeutic effect in autoimmune disease patients.

3:30pm – 4:00pm

Plasticity of Th Cells

John J. O'Shea, MD

NIH

4:00pm – 4:30pm

Dual Role of Retinoic Acid in Intestinal Immunity

Bana Jabri, MD, PhD

University of Chicago

4:30pm – 4:45pm

CD6 Targeted Immunotherapy Controls Inflammation in Autoimmune Diseases

Enrique Montero, MD, PhD

Center of Molecular Immunology

4:45pm – 5:00pm

In Situ Detection of Islet Antigen-Specific CD8 T Cells in Insulitic Lesions of Type I Diabetes Patients

Matthias von Herrath, MD

La Jolla Institute for Allergy & Immunology

5:00pm – 5:15pm

Correlation of a Blood Cell-Based Molecular Signature with Immunopathogenesis in Celiac Disease

Mitchell Garber

Alvine Pharmaceuticals Inc.

5:15pm – 5:30pm

Generation of Regulatory Dendritic Cells for Graft-Versus-Host Disease Therapy from Older Healthy Donors and Bone Marrow Transplant Recipients Under Clinically Relevant Conditions

Sabrina Scroggins, BS

University of Iowa

5:30pm – 6:00pm

CIS Business Meeting

5:30pm – 7:30pm

Poster Reception

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



SATURDAY, MAY 21

6:30am – 8:30am Breakfast

7:00am – 8:30am **The Patient, the Physician, and the Payor: A Multiperspective Look at the Challenges of Treating Primary Immunodeficiency Disease**

7:00am Introduction and Objectives
Mark Ballow, MD (Co-Chair)
SUNY Buffalo

7:05am Dosing & Therapy Utilization
Elena E. Perez, MD, PhD (Co-Chair)
University of South Florida
All Children's Hospital
Mark Ballow, MD
SUNY Buffalo

7:25am Payor Issues From the Standpoint of the Patient, Physician, and Payor: A panel discussion on issues related to formulary choices, sites of care, routes of administration, and insurance coverage
Ralph S. Shapiro, MD
Midwest Immunology Clinic
Marcia Boyle
Immune Deficiency Foundation

8:00am Advocacy Support: A discussion of local and national advocacy efforts to ensure that patients with PIDD are treated appropriately
Marcia Boyle
Ralph S. Shapiro, MD
Elena E. Perez, MD, PhD

8:25am Conclusions
Elena E. Perez, MD, PhD
Mark Ballow, MD

Session supported by **Baxter**

8:30am – 10:45am **Immune Checkpoint Blockade as Cancer Therapy**

Credit: 2.25 CME

Upon completion of this session, participants should be able to: understand the principles of immune regulation; and learn about the translation of new basic discoveries in cancer immunology, into effective cancer immunotherapies.

8:30am – 9:00am CTLA-4 Blockade
Jim Allison, MD, PhD
Memorial Sloan-Kettering Cancer Center

9:00am – 9:30am Implicating the ICOS/ICOSL Pathway as a Target for Cancer Immunotherapy
Padmanee Sharma, MD, PhD
MD Anderson Cancer Center

9:30am – 9:45am Induction of NKT Cell-Specific Immune Responses in Cancer Tissues after NKT Cell-Targeted Adoptive Immunotherapy
Kazuki Yamasaki, MD
Graduate School of Medicine, Chiba University

9:45am – 10:15am Adoptive Transfer of T cells
Carl June, MD
University of Pennsylvania

10:15am – 10:45am Anti-PD-1 in Clinical Trials
Suzanne Topalian, MD
Johns Hopkins University

10:45am – 11:00am Break

11:00am – 12:30pm **Future Technologies / Sequencing**

Credit: 1.5 CME

Upon completion of this session, participants should be able to: understand the role of anticytokine autoantibodies in immunodeficiency; recognize diseases commonly associated with anticytokine autoantibodies; understand important characteristics of antibodies that may influence disease manifestations: titer, functionality, IgG subclass; and identify common infections associated with anti-IFN-g autoantibodies.

11:00am – 11:30am Speaker TBD

11:30am – 12:00pm Restoring Immune Regulation in Human Autoimmune Disease: Peptide Vaccines and Stem Cell Transplants
Syamal Datta, MD
Northwestern University Feinberg School of Medicine



SATURDAY, MAY 21 — CONTINUED

- 12:00pm – 12:15pm Mapping Immune Cell Signaling Network Responses using Single Cell Network Profiling in Peripheral Blood Mononuclear Cells from Healthy Donors: Defining “Normal”
Diane Longo, PhD
Nodality
- 12:15pm – 12:30pm Acquired Immunodeficiency due to Anti-Interferon-Gamma Autoantibodies in HIV Negative Asian Adults
Sarah Browne, MD
National Institutes of Allergy & Infectious Diseases, NIH
- 12:30pm – 1:30pm Lunch Break
- 1:30pm – 3:00pm Novel New Diagnostics**
Credit: 1.5 CME
- 1:30pm – 2:00pm Use of Mass Spec Flow for Multi-Parameter Analysis
Erin Simonds, BS
Stanford University School of Medicine
- 2:00pm – 2:30pm Immune Profiling by High-Throughput Sequencing of B and T Cell Receptors
Harlan Robins, PhD
Fred Hutchinson Cancer Research Center
- 2:30pm – 3:00pm Speaker TBD
- 3:00 pm – 3:30 pm Break
- 3:30pm – 5:30pm B Cells: They Regulate Too, You Know**
Credit: 1.75 CME
Upon completion of this session, participants should be able to: understand B cell biology in general; tolerance; immunosuppression; Rituximab; and autoimmunity.
- 3:30pm – 4:00pm Regulatory B Cells in Health and Disease
Claudia Mauri, PhD
University College London
- 4:00pm – 4:30pm Getting to the Center of the Germinal Center
Michel Nussenzweig, MD, PhD
The Rockefeller University
- 4:30pm – 4:45pm Generation of Autoantibodies in Dendritic Cell Specific Blimp-1 Deleted Mice
Sun Jung Kim, PhD
The Feinstein Institute for Medical Research
- 4:45pm – 5:15pm B Cell in CVID
Charlotte Cunningham-Rundles, MD, PhD
Mt. Sinai Medical Center
- 5:30pm – 7:30pm Poster Reception

SUNDAY, MAY 22

- 7:30am – 8:30am Breakfast
- 8:30am – 10:45am Innate Immunity, Finally Getting Some Respect**
Credit: 2.25 CME
Upon completion of this session, participants should be able to: understand the basic mechanisms of innate immune activation; define the role of Toll like receptors in bacterial and parasitic infections; learn of the potential for microbial DNA to mediate serious complications of infection; learn of potential new therapies for fatal complications of plasmodial infections.
- 8:30am – 9:00am Monocytes and Macrophages in Atherosclerosis
Klaus Ley, MD
La Jolla Institute for Allergy & Immunology
- 9:00am – 9:30am Plasmacytoid Dendritic Cells at the Interface of Viral Control and Autoimmunity
Marco Colonna, MD
Washington University School of Medicine
- 9:30am – 10:00am The Role of Innate Lymphoid Cells in Influenza Infection in the Lung
Dale Umetsu, MD, PhD
Harvard Medical School
- 10:00am – 10:30am TLR Signaling
Douglas Golenbock, MD
University of Massachusetts
- 10:30am – 10:45am X-linked Hyper-IgM Patients Present Neutrophil Toll Like Receptor 2 Deficiency Resulting in Defective Respiratory Burst Response that can be Reversed by Exogenous IFN-gamma
Otavio Marques
Universidade de Sao Paulo
- 10:45am – 11:00am Break
- 11:00am – 12:00pm Life-Threatening Infectious Diseases of Childhood: Single-Gene Inborn Errors of Immunity?
Credit: 1 CME
Jean-Laurent Casanova, MD, PhD
The Rockefeller University

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



POSTER PRESENTERS

POSTER NUMBER	POSTER TITLE	PRESENTER NAME	PRESENTER INSTITUTION
1	Evaluation of basophil-associated CCR3 expression to determine functional responsiveness of basophils in chronic urticaria patients.	Aaruni Khanolkar	University of Utah
2	Similar IgG Stabilization in Glycine and L-proline Formulated 10	Adam Sun	Baxter BioScience
3	Factors that Affect Health-Related Quality of Life in Patients with Primary Immunodeficiency Disease	Andrew Ayars	University of Washington
4	NFAT is a master regulator of macrophage-dependent immunomodulatory effects of alcohol abuse	Angela Dolganiuc	UMass
5	Probable case of Mendelian Susceptibility to Mycobacterial diseases. Case presentation.	Aristoteles Alvarez Cardona	Star Medica
6	Hemophagocytic Lymphohistiocytosis Syndrome in a Patient with Chronic Granulomatous Disease and Fungemia	Brant Ward	Virginia Commonwealth University Health System
7	Cytomegalovirus (CMV) and Recurrent Atypical Mycobacterial Infections in a Child with Complete Interferon-Gamma-Receptor-1 (IFNgR1) Deficiency	Brian Tison	Baylor College of Medicine
8	Successful bone marrow transplant in a patient with MHC class II deficiency and rubella viremia post-vaccination	Burcin Uygungil	Cincinnati Children's Hospital Medical Center
9	Clinical evaluation in patients with Common Variable Immunodeficiency after administration of polysaccharide and protein antigens	C. Kokron	University of São Paulo Medical School
10	ATTENUATION OF ALLERGEN-INDUCED INTESTINAL INFLAMMATION AND IMMUNOGLOBULIN E PRODUCTION BY ARECA NUT EXTRACT IN A MURINE MODEL OF FOOD ALLERGY	Chia-Chi Wang	National Taiwan University
11	An Atypical Case of JAK3 SCID?	Christian Wysocki	Yale
12	Trafficking of vacuolar ATPase in activated neutrophils	Colleen Lewis	Rosalind Franklin University of Medicine and Science
13	FACILITATED SUBCUTANEOUS DELIVERY OF IGG WITH RECOMBINANT HUMAN HYALURONIDASE (RHUPH20): ASSESSMENT OF SURROGATE TOLERABILITY ENDPOINTS	David Kang	Halozyme Therapeutics, Inc.
14	Cause of death in infants with an abnormal or inconclusive T cell receptor excision circle (TREC) assay on newborn screening for severe combined immune deficiency (SCID)	Deborah Accetta	Medical College of Wisconsin and the Children's Research Institute
15	Novel mutations in MVK associated with hyperimmunoglobulinemia D with periodic fever syndrome phenotype	Dewton de Moraes-Vasconcelos	Faculdade de Medicina da Universidade de Sao Paulo
16	Good syndrome – a complex late-onset immunodeficiency	Dewton de Moraes-Vasconcelos	Faculdade de Medicina da Universidade de Sao Paulo
17	Adverse outcome in the Association of Visceral Leishmaniasis and Combined Immunodeficiency	Dewton de Moraes-Vasconcelos	Faculdade de Medicina da Universidade de Sao Paulo
18	Disseminated warts in a patient presenting a complex cellular immunodeficiency with new immunological features	Dewton de Moraes-Vasconcelos	Faculdade de Medicina da Universidade de Sao Paulo



POSTER PRESENTERS

POSTER NUMBER	POSTER TITLE	PRESENTER NAME	PRESENTER INSTITUTION
19	Spectrum of presentations of disseminated warts among immunodeficient patients in a specialized dermatology outpatient unit care	Dewton de Moraes-Vasconcelos	Faculdade de Medicina da Universidade de Sao Paulo
20	Esophageal rupture in an apeced patient	Dewton de Moraes-Vasconcelos	Faculdade de Medicina da Universidade de Sao Paulo
21	CD27 expression in T cells as a surrogate marker for autoimmunity among Common Variable Immunodeficiency	Dewton de Moraes-Vasconcelos	Faculdade de Medicina da Universidade de Sao Paulo
22	A Retrospective Review of Two Patients with Severe Primary Immunodeficiency Disease and the Factors Affecting Decision for Hematopoietic Stem Cell Transplantation	Diana Bayer	Children's Hospital of Michigan
23	Treatment Costs Associated with Hospital-Based Intravenous Immunoglobulin Therapy Compared to Home-Based Subcutaneous Immunoglobulin Therapy in a Cohort of Patients with Primary Immunodeficiency Treated at a Paediatric Hospital in Montreal, Canada	Elie Haddad	CHU Sainte-Justine, Université de Montréal
24	Short duration of untreated disease is associated with increased VCAM-1 expression in juvenile dermatomyositis diagnostic muscle biopsies	Erin Kim	Northwestern University
25	Post-trauma Increased CD47-Thrombospondin-1 (TSP-1) Signaling May Contribute to Inhibitory DC Development by inhibiting STAT6 and Decreasing Costimulatory Receptors	Gautam Bandyopadhyay	University of Rochester Medical Center
26	Non-caseating Granulomas and B-cell Immunodeficiency in a Patient with DiGeorge Syndrome	Hana Niebur	Advocate Hope Children's Hospital
27	T-cell mediated cross-reactivity between human and Malassezia sympodialis thioredoxin in adult patients with atopic dermatitis	Hari Balaji Venkatanarayanan	Medizinische Hochschule Hannover
28	Tolerability of Human Immunoglobulin 10	Isaac Melamed	ImmunoE Health Centers
29	Subcutaneous immunoglobulins: Product characteristics and their role in primary immunodeficiency disease	Isaac Melamed	IMMUNOe International Research Center
30	Acquired Complement Deficiency Secondary to C3 Nephritic Factor Autoantibody in a Child with Neisseria meningitidis Infection	Jeana Bush	Levine Children's Hospital at Carolinas Medical Center
31	Corticosteroid Therapy in Refractory Liver Abscesses in Chronic Granulomatous Disease	Jennifer Leiding	NIH /NIAID/LCID
32	Rapid Clearance of L-Proline After Intravenous and Subcutaneous Infusion With L-Proline–Stabilized Immunoglobulin Replacement Products	John Hagan	Mayo Clinic
33	Nine Year Old Male with Short Staure, Chronic Herpetic Infections and Colitis	Jolan Walter	Massachusetts General Hospital
34	SAFETY AND TOLERABILITY OF SUBCUTANEOUS IMMUNOGLOBULIN THERAPY WITH PREPARATIONS LICENSED IN BRAZIL FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION.	Jose Marcos Cunha	Federal University of Rio de Janeiro School of Medicine

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



POSTER PRESENTERS

POSTER NUMBER	POSTER TITLE	PRESENTER NAME	PRESENTER INSTITUTION
35	Severe autoimmunity with polyarticular joint disease requiring anti-TNF therapy and T+B-NK+ immunodeficiency in a family with small stature and intermediate radiation sensitivity	Jun Lu	University of Washington
36	The first two cases of Familial Haemophagocytic Lymphohistiocytosis type II due to PRF1 gene mutations in Colombia	Lucia Leal-Esteban	University of Antioquia
37	SEVERE COMBINED IMMUNODEFICIENCY IN BRAZIL: A MULTI-CENTER ANALYSIS OF DEMOGRAPHICS, CLINICAL FEATURES REGARDING BCG INFECTION AND OUTCOME IN 33 PATIENTS	Luciana Cunha	Federal University of Sao Paulo
38	Chronic Granulomatous Disease Brothers developed viral infections during corticosteroid treatment.	Luciana Cunha	Federal University of Minas Gerais
39	Common variable immunodeficiency: broad spectrum of complications in the same patient	Juliana Nunes	Federal University of Minas Gerais
40	Defects on the IFN-gamma/IL-12 Axis: a case report	Tiago Guimarães	Federal University of Minas Gerais, School of Medicine
41	Characteristics and outcome of immune thrombocytopenia in adults: an observational study of 293 patients seen at diagnosis at a French referral center	Maria Chauchard	Henri Mondor Hospital
42	ABSENCE OF PROCOAGULANT ACTIVITIES IN THE PASTEURIZED PRODUCTS FLEBOGAMMA® AND FLEBOGAMMA® DIF	Marta José	Instituto Grifols S.A.
43	T-Helper (Th)1 and Th2 Cytokines in Atherosclerosis and Effects of Vitamin A Supplementation on Th1/Th2 Balance	Maryam Mahmoudi	Tehran University of Medical Sciences
44	Maintenance of Memory-like NK cells Following Expansion in a Lymphopenic Host	Megan Cooper	Washington University School of Medicine
45	A Case of Pediatric Immunodeficiency	Michael Eckrich	CIBMTR/Medical College of WI
46	Complement Deficiency in a 3 year-old male	Nancy Wasserbauer	Akron Children's Hospital
47	Combination Chemotherapy Improves Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Patients with Common Variable Immunodeficiency (CVID)	Nicole Chase	Medical College of Wisconsin
48	Soluble CD30 as a Marker of Disease Severity in Common Variable Immunodeficiency	Nima Rezaei	Tehran University of Medical Sciences
49	A Case of HyperIgE Syndrome: To Transplant or Not to Transplant?	Niraj Patel	Levine Children's Hospital
50	Dendritic cells from CD40 ligand deficient patients present altered responses to Candida albicans and Paracoccidioides brasiliensis	Otávio Marques	Universidade de São Paulo
51	In vivo BAY 41-2272 treatment activates peritoneal macrophages and augments carragenin-induced inflammation in mice	Paulo Soeiro-Pereira	University of São Paulo
52	BAY 41-2272 activates human lymphocytes: a potential drug for treating patients with immunodeficiency	Paulo Soeiro-Pereira	University of São Paulo



POSTER PRESENTERS

POSTER NUMBER	POSTER TITLE	PRESENTER NAME	PRESENTER INSTITUTION
53	Autoimmune lymphoproliferative syndrome (ALPS) enteritis in an infant with an intron 4 mutation (IVS4 mutation)	Rajashri Iyengar	Massachusetts General Hospital
54	Pharmacokinetics (PK) of Human Immunoglobulin 10	Richard Wasserman	Dallas Allergy Immunology Research
55	Safety, Efficacy, Tolerability And Pharmacokinetics Of A New 10	Richard Wasserman	Dallas Allergy Immunology Research
56	DRESS SYNDROME, A Case Report	Rocio Zeballos-Chavez	Wayne State University/DMC
57	A Clinically Validated Flow Cytometric Method Using Edu® To Measure Lymphocyte Proliferative Responses: Alternatives For The Clinical Immunology Laboratory	Roshini Abraham	Mayo Clinic
58	A case report of Burkholderia cepacia lung infection in a teenager with common variable immunodeficiency.	Sahar Faghih	Children's Hospital of Michigan
59	Clinical Profile of Children with Auto-inflammatory Periodic Fever Syndromes from a single center in South East Michigan.	Shanmuganathan Chandrakasan	Children's Hospital of Michigan
60	Local Tolerability of Subcutaneous Infusions With 20	Sheldon Spector	University of California, and California Allergy & Asthma Medical Group Inc
61	Completely impaired degranulation and cytotoxicity in two siblings with Chediak Hegashi Syndrome	Sherif Badawy	Faculty of Medicine, Zagazig University
62	Modulation of serum Interleukin-8 concentrations during the natural course of acute hepatitis B and during interferon- α therapy in patients with HBeAg-positive chronic hepatitis B.	Staffan Sylvan	Uppsala County Council
63	Recurrent deep-seated staphylococcus aureus infections of unclear etiology.	Tara Carr	Northwestern University Feinberg School of Medicine
64	A case example of clinical cytometry based cellular phenotyping and functional analysis complementing genetic studies	Trivikram Dasu	Medical College of Wisconsin
65	Factors that affect the Health-Related Quality of Life in Patients with Primary Immunodeficiency Disease	Troy Torgerson	University of Washington
66	Early recognition of C2 Complement deficiency during infancy.	Usha Phillips	WVU Children's Hospital
67	Pathogen safety and biochemical characterization of a new 10	Vijayan Nair	Octapharma USA
68	Anti-inflammatory Action of Xinkong in ApoE-/- Mice	Xuguo Liang	Qingdao University, School of Medicine
69	Antigen specific cellular response in patients with Hepatitis C virus infection and its association with HLA alleles	Chinmaya Mahapatra	dybbi, india
70	Splicing Mechanism of NADPH-oxidase Genes on Chronic Granulomatous Disease Patient can be Influenced by IFN-Gamma Treatment	Josias Frazao	ICB-USP
71	NEMO-syndrome mutations and ubiquitin-binding	Jevgenia Rudenko	National Institutes of Health

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



CHECK OUT OUR NEW JOURNAL!

ABOUT THE *JOURNAL OF CLINICAL IMMUNOLOGY*

The *Journal of Clinical Immunology* is a bimonthly international journal that helps researchers and academic clinicians keep current on investigative basic immunology and diseases related to the immune system. This well-established journal publishes articles on basic, translational, and clinical studies in all aspects of immunology, including animal models of human diseases. The OnlineFirst™ feature allows articles to be viewed through the journal's website before they are available in the printed journal. The *Journal of Clinical Immunology* is the official journal of the Clinical Immunology Society.



Editor-in-Chief:

Thomas Fleisher
Bethesda, MD

Deputy Editor-in-Chief:

Kathleen Sullivan
Children's Hospital of Pennsylvania
Philadelphia, PA

Associate Editors:

Zuhair Ballas
University of Iowa
Iowa City, IA

Horace Delisser
University of Pennsylvania School of
Medicine
Philadelphia, PA

Robert Eisenberg
University of Pennsylvania School of
Medicine
Philadelphia, PA

Luigi D. Notarangelo
Harvard University Children's Hospital
Boston, MA

Lawrence Schwartz
Virginia Commonwealth University
Richmond, VA

Ricardo Sorensen
Louisiana State University Health Services
Center
New Orleans, LA

Editorial Board:

Daniel Adelman
University of California at San Francisco
San Francisco, CA

Basel K Al-Ramadi
United Arab Emirates University
United Arab Emirates

David Asmuth
University of California at Davis Medical
Center
Sacramento, CA

Mel Berger
CSL Behring
New Orleans, LA

Jack J L Bleesing
Cincinnati Children's Hospital Medical
Center
Cincinnati, Ohio

Francisco Bonilla
Harvard University Children's Hospital
Boston, MA

Fabio Candotti
National Human Genome Research
Institute, National Institute of Health
Bethesda, MD

Jean-Laurent Casanova
Rockefeller University
New York, NY

Talal Chatila
University of California at Los Angeles
Los Angeles, CA

Antonio Condino-Neto
University of São Paulo
São Paulo, Brazil

Mort Cowan
University of California at San Francisco
San Francisco, CA

Charlotte Cunningham-Rundles
Mount Sinai Medical Center
New York, NY

Ann Davidson
The Feinstein Institute for Medical
Research
Manhasset, NY

Alessio Fasano
University of Maryland School of Medicine
Baltimore, MD

Lisa Filipovich
Cincinnati Children's Hospital Medical
Center
Cincinnati, Ohio

Andrew Fontenot
University of Colorado Health Sciences
Center
Denver, CO

Terry Fry
Children's National Medical Center
Washington, DC

Daniel Fowler
National Cancer Institute
Bethesda, MD

Andrew Gennery
Newcastle University
New Castle Upon Tyne, United Kingdom

Anete Grumach
Alameda Santos
Sao Paulo, Brazil

Hal Hoffman
University of California at San Diego
San Diego, CA

Steve Holland
National Institute of Health
Bethesda, MD

Michael J Holtzman
Washington University School of Medicine
St. Louis, MO

David Huston
The Methodist Hospital Research Institute
Houston, TX

Carl June
University of Pennsylvania School of
Medicine
Philadelphia, PA

Naynesh Kamani
Children's National Medical Center
Washington, DC

Donald Kohn
University of California at Los Angeles
Los Angeles, CA

Manuel Comabella Lopez
Orphanet-Spain
Barcelona, Spain

Harry Malech
National Institute of Health
Bethesda, MD

Toshinori Nakayama
Chiba University
Chiba, Japan

Kim Nichols
The Children's Hospital of Philadelphia
Philadelphia, PA

Joao Bosco Oliveira
National Institute of Health
Bethesda, MD

Jordan Orange
The Children's Hospital of Philadelphia
Philadelphia, PA

Ken Olivier
National Institute of Allergy and Infectious
Disease
Bethesda, MD

Andras Perl
SUNY Upstate Medical Center
Syracuse, NY

Susan Plaeger
National Institute of Allergy and Infectious
Disease
Bethesda, MD

Jennifer Puck
University of California at San Francisco
San Francisco, CA

Aaron Rapoport
University of Maryland School of Medicine
Baltimore, MD

Marc Riedl
University of California at Los Angeles
Los Angeles, CA

Jack Routes
Medical College of Wisconsin
Milwaukee, WI

Padmanee Sharma
MD Anderson
Houston, TX

John W. Sleasman
University of South Florida
St. Petersburg, FL

Dave Teachey
Children's Hospital of Philadelphia
Philadelphia, PA

Troy Torgerson
University of Washington
Seattle, WA

Dewton de Moraes Vasconcelos
University of Sao Paulo Medical School
Sao Paulo, Brazil

Matthias Von Herrath
La Jolla Institute for Allergy and
Immunology
San Diego, CA

Mission Statement

The mission of the Clinical Immunology Society is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders.

About CIS: Objectives and Purposes

The Clinical Immunology Society (CIS), established in 1986, is devoted to fostering developments in the science and practice of clinical immunology. The primary objectives and purposes of this Society shall be to:

1. facilitate the interchange of ideas and information among physicians and other investigators who are concerned with immunologic/inflammatory diseases;
2. promote research on the causes and mechanisms of diseases relating to the immune system and, as a result, to unify concepts of disease pathogenesis;
3. encourage investigators and clinicians to share their knowledge of immunologically active drugs and other interventions;
4. promote application and dissemination of recent advances in biomedical science for the prevention, diagnosis and treatment of diseases related to immunity and inflammation and;
5. foster excellence in research and medical practice.

Membership Benefits

The benefits of membership in the Clinical Immunology Society include:

- The opportunity to be involved in a dynamic society devoted to fostering the development of clinical immunology.
- Reduced registration fees to the CIS Annual Meeting & Primary Immune Deficiency National Conference.
- Complimentary online subscription to the *Journal of Clinical Immunology*, the official peer-reviewed scientific journal of the Clinical Immunology Society;
- Opportunities to advance your career by serving on CIS Committees or serving as faculty for CIS Schools and meetings;
- Access to the CIS Membership Directory and beneficial links on the CIS website, www.clinimmsoc.org.
- Belonging to an association that is accredited by the Accreditation Council for Continuing Medical Education to sponsor CME for physicians;
- Reduced FOCIS Annual Meeting Registration fees;
- Access to virtual meeting content through the CIS website.

Membership Categories and Requirements

Regular membership shall be open to those individuals who:

- are engaged in research in the area of clinical immunology or have contributed to or are engaged in the practice of clinical immunology;
- have an MD, DO, PhD or equivalent academic degree;
- are active, bona fide representatives of the international scientific community with a specialty or interest in a field related to clinical immunology.

Associate membership shall be open to those individuals who:

- hold a Bachelors, Masters, RN or equivalent degree with a demonstrated interest in clinical immunology.

Trainee membership shall be open to those individuals who:

- are enrolled in academic programs awarding, and are candidates for, MD, DO, PhD, or equivalent degree, with a demonstrated interest in clinical immunology.
- are participating in post-doctoral or clinical fellowship, or residency programs.

Members from Developing Countries

Members from developing countries are eligible for a 50% reduction of membership fees upon request.

Application Process

Applicants for **Regular** and **Associate** membership must submit:

- a CIS membership application;
- a current curriculum vitae;
- the first year's dues with application.

Applicants for **Trainee** membership must submit:

- a CIS membership application;
- the first year's dues with application;
- a letter from the training program director on institution letterhead that includes:
 - Date
 - Name of applicant
 - Beginning and ending dates of applicants training program
 - Type of work performed and professional ability
 - Character and ethical standing
 - Applicant's special interest in clinical immunology
 - General statement to recommend applicant for membership

Clinical Immunology Society

555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA

Telephone: 414.224.8095
Fax: 414.272.6070
info@clinimmsoc.org

The Science & Practice of Human Immunology

First Name _____ Middle Initial _____ Last Name _____
 Designation (MD, PhD, other) _____ Current Position/Title _____
 Date of Birth _____ Training Start Date _____ Training End Date _____
 Institution _____
 Current Research Interest(s) (up to 3) _____
 Preferred Mailing Address: Business Home
 Business Address _____
 City _____ State _____ Postal Code/Country _____
 Business Phone _____ Fax _____
 E-mail _____
 Home Address _____
 City _____ State _____ Postal Code/Country _____
 Home Phone _____

Please select to be listed on the Find an Immunologist Directory:

- I would like to be listed in the on-line Find an Immunologist Referral Directory
 must be clinically active to qualify

Journal of Clinical Immunology – Official Journal of the Clinical Immunology Society

As a CIS member you are entitled to receive electronic access. You may add a print subscription for an additional \$20.

- I DO wish to receive the print subscription to the CIS Journal at a cost of \$20.

Affiliations (check all that apply):

- Industry Private Practice
 Medical School Research University
 Military NIH/FDA
 Other _____

Specialty (check all that apply):

- Allergy/Asthma/Pulmonary Immunodeficiency
 Autoimmunity Immunogenetics
 Cardiovascular Immunotherapy
 Cytokines MS/Neuroimmunology
 Dermatology Mucosal Immunology
 Diagnostic/Laboratory Pathology
 Immunology Ophthalmology
 Endocrinology Reproductive Immunology
 Gastroenterology Rheumatology
 Hematology Transplantation
 HIV/Infectious Diseases Tumor Immunology
 Histocompatibility Other _____

Thank you for your interest in the Clinical Immunology Society.

Please return application to:
 Clinical Immunology Society • 555 East Wells Street, Suite 1100
 Milwaukee, WI 53202-3823 USA • **Telephone:** 414.224.8095
Fax: 414.272.6070 • info@clinimmsoc.org • www.clinimmsoc.org

Membership Category

- Regular – 3+ years out of training.....\$150*
 Regular – 2 years out of training/training completed in 2008.....\$75*
 Regular – 1 year out of training/training completed in 2009.....\$50*
 Associate.....\$150*

Documents required for Regular & Associate Membership:

- Current Curriculum Vitae

- Trainee.....\$35*

Name of training program director _____

Documents required for Trainee Membership

- Letter from Training Program Director

**Dues must be submitted with your application.*

Members from Developing Countries

- As a member from a developing country I am requesting a 50% discount on membership dues.

Please consider making a donation to CIS

- General Donation Amount: \$ _____
 Educational Programs Amount: \$ _____

Total amount enclosed / authorized to charge

\$ _____

Payment Method:

- Check (in US dollars payable to Clinical Immunology Society)
 VISA MASTERCARD
 DISCOVER AMERICAN EXPRESS

Cardholder Name _____ Cardholder Signature _____

Card Account Number _____

Expiration Date _____ 3 Digit Security Code
 (4 Digits for AmEx)

CIS 2011 ANNUAL MEETING

May 19-22, 2011 • Chicago, IL



THANK YOU TO OUR ANNUAL MEETING SUPPORTERS!

SILVER LEVEL

GRIFOLS

CORPORATE SESSION SUPPORTERS

Baxter

CSL Behring

Biotherapies for Life™

COLLABORATING PARTNERS



LA JOLLA INSTITUTE
for
ALLERGY & IMMUNOLOGY



2nd Primary Immune Deficiency NATIONAL CONFERENCE

May 17 - 20, 2012
Swissôtel, Chicago, IL

Purpose

The purpose of this meeting is to provide an intellectual forum for all clinicians and researchers from around the world to discuss diagnosis, pathogenesis, and management of primary immunodeficiency diseases.

Target Audience

The target audience for the meeting is physicians and researchers working in the primary immunodeficiency disease field but is open to infectious disease, hematology, oncology, allergy, and transplant experts as well as anyone with an interest in immunodeficiency.

Objectives

The objectives of this conference are to:

- Enhance the knowledge of physicians and basic science researchers in the field of immunology;
- Enhance the understanding of the pathologic processes in various primary immunodeficiencies;
- Ultimately lead to improved patient care;
- Benefit investigators and clinicians from the intense focus on primary immunodeficiencies and the opportunity to hear cutting edge research.

Course Description

This two and a half day meeting will feature didactic presentations by leaders in the field. Through lectures, panel discussions and networking during the meeting, clinicians and researchers will come away with an improved knowledge of primary immunodeficiencies. In addition to the formal presentations there will also be poster sessions and scheduled breaks to allow for networking.

Meeting Dates and Venue

The conference will be held from May 17-20, 2012 at the Swissôtel in Chicago, IL.

Registration

Registration for the conference will open in November. Please watch the CIS website for further information.

Questions? Please contact Michelle Roach, CIS Associate Director of Programs, by phone at (414) 224.8095 or by e-mail at mroach@clinimmsoc.org.